Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/27/2024 | $5.00 | Outperform | BMO Capital Markets |
| 4/9/2024 | $9.00 | Overweight | Piper Sandler |
| 2/1/2023 | $14.00 → $1.50 | Buy → Hold | Jefferies |
| 1/27/2023 | $23.00 → $3.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/9/2022 | $16.00 → $3.00 | Buy → Neutral | Goldman |
| 3/9/2022 | $26.00 | Outperform | Robert W. Baird |
| 3/9/2022 | $26.00 | Outperform | Baird |
| 3/1/2022 | $25.00 | Overweight | Wells Fargo |
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the full-year ended December 31, 2020 and provided a corporate update. “In 2020, we successfully completed one of the fastest seed to IPOs in biotech history and made significant strides in advancing our pipeline initiatives, next-generation technology platforms and manufacturing strategy,” said RA Session II, President, Founder and CEO o
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced new additions to its leadership team with the appointments of Timothy J. Douros, J.D., as Chief Legal Officer and Corporate Secretary and Tracy M. Porter, M.Ed., SPHR, as Chief People Officer. Mr. Douros will lead all aspects of the company’s legal organization. Ms. Porter will oversee all aspects of human resources, including operations, talent acquisition and employee development.
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SC 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
BMO Capital Markets initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $5.00
Piper Sandler initiated coverage of Taysha Gene Therapies with a rating of Overweight and set a new price target of $9.00
Jefferies downgraded Taysha Gene Therapies from Buy to Hold and set a new price target of $1.50 from $14.00 previously
DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 3, 2025, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 225,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; update on pivotal trial design expected in H1 2025 Clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in H1 2025 Conference call and live webcast today
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call DetailsWednesday, February 26, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: https://ir.tayshagtx.com/news-events/events-p
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; update on pivotal trial design expected in H1 2025 Clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in H1 2025 Conference call and live webcast today
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call DetailsWednesday, February 26, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: https://ir.tayshagtx.com/news-events/events-p
High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two (high dose) across both REVEAL trials; eight patients dosed to date (low dose=4, high dose=4) Advanced discussions with the FDA on trial design, endpoints and potential use of established natural history dataset for Part B of REVEAL trials, and aligned on a meeting cadence to expedite the development plan for TSHA-102 following initial RMAT Type B meeting FDA approved use of pivotal TSHA-102 product in REVEAL trials based on successful demonstration of analytical comparability; Company released pi
10-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)